Source: Annual Congress 2002 - Drug resistance
Disease area: Respiratory infections

Abstract

Sixty-five patients (aged 20 years to 45 years) of multi-drug resistant tuberculosis (MDR-TB) were given 400 of sparfloxacin along with kanamycin, ethionamide and ethambutol under direct supervision. All patients were HIV negative, smear-positive, non-pregnant and had been receiving antituberculosis drugs for an average of 42 weeks (range 26 to 90 weeks). All patients had isolates resistant to both isoniazid and rifampicin. Kanamycin was given in the dose of 25mg/kg body weight on alternate days for 16 weeks. Two patients were withdrawn from the trial because of kanamycin induced ototoxicity. Sparfloxacin was stopped in two patients because of severe photo toxicity and in one patient because of convulsions. Sixty of 65 patients received sparfloxacin for 12 months. After 20 weeks of therapy smear conversion was in 45(75%) and culture conversion in 40 (67%) patients. After 1 year of therapy 10 (17%) patients remained smear-positive.
Chemotherapy with sparfloxacin, kanamycin, ethionamide and ethambutol seems to be promising for the treatment of MDR-TB.

Rating:

Share or cite this content

Citations should be made in the following way:
S. K. Agarwal (Varanasi, India). Treatment outcome of multi-drug resistant tuberculosis in Varanasi, India. Eur Respir J 2002; 20: Suppl. 38, 3842

Member's Comments

No comment yet.

Related content which might interest you: Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Treatment outcome of multi-drug resistant tuberculosis in the Republic of Moldova Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Frequency of risk factors for multi-drug resistant tuberculosis among the patients enrolled at multi-drug resistant clinic in a tertiary care hospital, Pakistan Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 Outcome of multi-drug resistant tuberculosis in Belgrade Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India Source: Eur Respir J , 49 (3) 1601699; DOI: 10.1183/13993003.01699-2016 Year: 2017 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Genotypes and drug resistance patterns of multi-drug-resistant mycobacterium tuberculosis strains in Pakistan Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015 Treating extensively drug resistant tuberculosis (XDR-TB) in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004 Molecular epidemiology of multi drug resistance tuberculosis isolates from pulmonary tuberculosis cases from Lucknow, India Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 A tale of two settings: The role of the Beijing genotype in the rise of multidrug resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Treatment outcome of multi-drug resistant tuberculosis (MDR-TB) patients at a tertiary care center of Northern India. Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016 Emergence of drug resistance in mycobacterium tuberculosis isolates in Ibadan, Nigeria Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007 Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014